Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trial to Assess Chelation Therapy (TACT)

This study has been completed.
Sponsor:
Collaborators:
Information provided by (Responsible Party):
Gervasio Lamas, MD, Mt. Sinai Medical Center, Miami
ClinicalTrials.gov Identifier:
NCT00044213
First received: August 22, 2002
Last updated: August 30, 2013
Last verified: August 2013
Results First Received: August 30, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Factorial Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Coronary Artery Disease
Interventions: Drug: EDTA
Drug: EDTA Placebo
Dietary Supplement: High Dose Vitamin
Dietary Supplement: High Dose Vitamin Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The primary analysis of the trial included 1708 patients who had been enrolled from September 2003 through October 2011 (median, 55 months)Participants were recruited at 134 sites in the US and Canada.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
EDTA + High Dose Vitamin Participants will receive 40 infusions of active EDTA chelation and active high-dose oral vitamins.
EDTA + High Dose Vitamin Placebo Participants will receive 40 infusions of EDTA chelation and placebo high-dose oral vitamins.
EDTA Placebo + High Dose Vitamin Participants will receive 40 infusions of placebo EDTA chelation and active high-dose oral vitamins.
EDTA Placebo + High Dose Vitamin Placebo Participants will receive 40 infusions of placebo EDTA chelation and placebo high-dose oral vitamins.

Participant Flow:   Overall Study
    EDTA + High Dose Vitamin     EDTA + High Dose Vitamin Placebo     EDTA Placebo + High Dose Vitamin     EDTA Placebo + High Dose Vitamin Placebo  
STARTED     421     418     432     437  
COMPLETED     321     306     294     301  
NOT COMPLETED     100     112     138     136  
Withdrawal by Subject                 50                 65                 91                 83  
Death                 42                 42                 42                 49  
Lost to Follow-up                 8                 5                 5                 4  



  Baseline Characteristics


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   A Composite of Total Mortality, Recurrent Myocardial Infarction, Stroke, Coronary Revascularization, and Hospitalization for Angina.   [ Time Frame: Measured over a maximum 5-year follow-up period- 55 month median ]

2.  Secondary:   A Composite of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke.   [ Time Frame: Measured over a maximum 5-year follow-up period- 55 month median ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame No text entered.
Additional Description No text entered.

Reporting Groups
  Description
EDTA + High Dose Vitamin Participants will receive 40 infusions of active EDTA chelation and active high-dose oral vitamins.
EDTA + High Dose Vitamin Placebo Participants will receive 40 infusions of EDTA chelation and placebo high-dose oral vitamins.
EDTA Placebo + High Dose Vitamin Participants will receive 40 infusions of placebo EDTA chelation and active high-dose oral vitamins.
EDTA Placebo + High Dose Vitamin Placebo Participants will receive 40 infusions of placebo EDTA chelation and placebo high-dose oral vitamins.

Serious Adverse Events
    EDTA + High Dose Vitamin     EDTA + High Dose Vitamin Placebo     EDTA Placebo + High Dose Vitamin     EDTA Placebo + High Dose Vitamin Placebo  
Total, serious adverse events          
# participants affected / at risk     2/421 (0.48%)     0/418 (0.00%)     0/432 (0.00%)     2/437 (0.46%)  
Cardiac disorders          
Cardio-respiratory arrest          
# participants affected / at risk     1/421 (0.24%)     0/418 (0.00%)     0/432 (0.00%)     0/437 (0.00%)  
# events     1     0     0     0  
Cardiac Failure Congestive          
# participants affected / at risk     0/421 (0.00%)     0/418 (0.00%)     0/432 (0.00%)     2/437 (0.46%)  
# events     0     0     0     2  
General disorders          
Malaise          
# participants affected / at risk     1/421 (0.24%)     0/418 (0.00%)     0/432 (0.00%)     0/437 (0.00%)  
# events     1     0     0     0  




  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information